Novartis launches new USD 11 billion share buyback Ruchika Sharma13 March 2023 10:00 AM ISTZurich: Novartis has formally launched its new share buyback programme where it could spend up to 10 billion Swiss francs ($10.90 billion)...
Novartis, Teijin Pharma ink pact for preclinical candidate for proteinuric kidney diseases Ruchika Sharma8 March 2023 3:30 PM ISTTeijin Pharma will receive an upfront cash payment of USD 30 million from Novartis and is eligible to receive potential development and commercial...
Novartis names Gilbert Ghostine as Chairman designate of Sandoz Board of Directors Ruchika Sharma20 Feb 2023 3:30 PM ISTGhostine is an experienced business leader with a track record of growing and transforming businesses in competitive industries.
Operating profit to grow again ahead of Sandoz spin off: Novartis Ruchika Sharma1 Feb 2023 10:00 AM ISTNovartis said in its statement it's on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its...
Novartis gets European Commission nod for Pluvicto to treat progressive PSMA-positive metastatic castration-resistant prostate cancer Ruchika Sharma17 Jan 2023 3:30 PM ISTPluvicto is an intravenous radioligand therapy combining a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in...
EMA seeks to issue guidance on liver damage from Novartis gene therapy Zolgensma Ruchika Sharma15 Jan 2023 12:15 PM ISTThe drug won conditional EU approval during early 2020 and it costs more than $2 million per patient
Novartis gets CDSCO Panel nod to market anticancer drug Trametinib and Dabrafenib for additional indication Dr. Divya Colin1 Jan 2023 5:45 PM ISTNew Delhi: In a significant development, the drug major Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the...
Accused of trying to delay in launch of Hypertension drug generic, Novartis settles litigation with payment of Rs 2028 crore Ruchika Sharma29 Dec 2022 2:15 PM ISTNovartis and Par were accused of entering an illegal "reverse payment" agreement to delay launches of less expensive, generic versions of Exforge,...
Novartis gets CDSCO panel nod to study anticancer drug JDQ443 Dr. Divya Colin17 Dec 2022 6:00 PM ISTNew Delhi: Pharmaceutical major Novartis, has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Novartis prostate cancer therapy Pluvicto bags European Commission nod Ruchika Sharma14 Dec 2022 4:15 PM IST"The approval of Pluvicto by the European Commission marks a major milestone for patients with advanced prostate cancer who have few alternative...
Novartis considers selling ophthalmology, respiratory units to invest in cutting-edge medicines Ruchika Sharma17 Nov 2022 12:15 PM ISTAny sale of the ophthalmology and respiratory businesses is likely to begin in 2023, after the process for Sandoz is completed, the Bloomberg report...
Novartis allows generic Leukemia drug production in 7 nations: Bloomberg Ruchika Sharma21 Oct 2022 2:35 PM ISTChronic myeloid leukemia is a cancer that starts in the blood-forming cells found in bone marrow, before spilling into the general blood stream.
